Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siglec6 CAR-T
- Development stage
- Phase 2
- Lead developer
- Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Siglec6 CAR-T is an investigational chimeric antigen receptor T-cell (CAR-T) therapy that targets sialic acid–binding immunoglobulin-like lectin 6 (Siglec-6), a cell surface antigen highly expressed on acute myeloid leukemia (AML) cells and a subset of chronic lymphocytic leukemia (CLL) cells. The CAR uses a targeting domain derived from the JML-1 human monoclonal antibody. Preclinical studies show that Siglec6 CAR-T cells specifically eliminate AML blasts (including leukemic stem cells) and CLL cells, induce remission in AML xenograft models, and spare normal hematopoietic stem and progenitor cells (HSPCs), which do not express Siglec-6. This specificity offers the potential for effective leukemia clearance with a lower risk of myeloablation compared to other myeloid-targeted CAR-T therapies. Limited on-target off-tumor reactivity may occur, as Siglec-6 is also present on some mature B cells and basophils[1][2][5][8].
- Other names
- Siglec6 CAR-TSiglec-6 CAR-TSiglec 6 CAR-T
02
Targets
SIGLEC6 (Siglec-6)
Beyond the preview
Go deeper on Siglec6 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Siglec6 CAR-T.